Next-gen regenerative product manufacturer, Equus Innovations, has marketed AlphaFlo, its canine allograft. The company has also partnered with AlphaLogix, LLC in the marketing.
AlphaFlo is made up of an acellular liquid canine amniotic tissue allograft derived from amnion. The amnion, which is thought to have regenerative, anti-microbial, anti-inflammatory, and anti-fibrotic elements.
"The release of AlphaFlo by AlphaLogix is another exciting regenerative solution for veterinary patients,” said Grant D. Senner, MD, DABRM, and chief executive officer of Equus Innovations. “We are privileged to be partners in advancing these innovative allograft products."
Makeup of the allograft is gathered from healthy canines using sterile equipment during the process of birth without any harm to the animals. Equus also manufactures RenoVo equine allograft, which is sold by distributor Equine Amino Solutions, LLC.